

REMARKS

1. Claims 1, 2 and 4-7 remain in the application. The limitation of claim 3 has been incorporated into claim 1. Accordingly, claim 3 has been cancelled and the claim dependency of claim 4 has been changed from claim 3 to claim 2. Claim 6 has also been amended to change its claim dependency from claim 1 to claim 5.
2. Claims 1, 2, 6 and 7 were rejected under 35 U.S.C. 112, first paragraph, because it is asserted that the specification is only enabled for the halides represented by the formula set forth in claim 3. In response to this rejection, Applicants have incorporated the limitation of claim 3 into claim 1. Accordingly, this amendment now renders the rejection no longer applicable, and the rejection may now be withdrawn.
3. Claim 6 was rejected under 35 U.S.C. 112, second paragraph, as being indefinite because there is no antecedent basis in claim 1 for "benzalconium chloride" set forth in claim 6. The dependency of claim 6 has been changed from claim 1 to claim 5, and there is antecedent basis for bezalconium chloride in claim 5. Accordingly, this rejection may now be withdrawn.
4. Claims 1-7 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-17 of copending application no. 10/742,136. Applicants have attached a completed terminal disclaimer in compliance with 37 CFR 1.321[c] to overcome this provisional rejection. Accordingly, this provisional rejection may now be withdrawn.

5. Since all formal requirements appear to have been met, Applicants respectfully solicit a Notice of Allowance at the Examiner's earliest convenience.

Respectfully submitted,

/Matthew S. Goodwin/

Matthew S. Goodwin
Reg. No. 32,839

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-3849
Dated: June 13, 2005